These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33126942)

  • 1. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?
    Ndjeka N; Hughes J; Reuter A; Conradie F; Enwerem M; Ferreira H; Ismail N; Kock Y; Master I; Meintjes G; Padanilam X; Romero R; Schaaf HS; Riele JT; Maartens G
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1073-1080. PubMed ID: 33126942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
    Masuku SD; Berhanu R; Van Rensburg C; Ndjeka N; Rosen S; Long L; Evans D; Nichols BE
    Int J Tuberc Lung Dis; 2020 Apr; 24(4):376-382. PubMed ID: 32317060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
    Fekadu G; Yao J; You JHS
    PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam.
    Nguyen TMP; Nguyen BH; Hoang TTT; Nguyen HA; Vu DH; Nguyen MH; Nguyen BN; Decroo T; Nguyen VN
    Front Pharmacol; 2022; 13():1023704. PubMed ID: 36313324
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early mortality during rifampicin-resistant TB treatment.
    Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
    Rikhotso MC; Ledwaba SE; Ngandu JK; Mavumengwana V; Kinnear CJ; Warren R; Potgieter N; Traoré AN
    Int J Tuberc Lung Dis; 2023 Aug; 27(8):599-605. PubMed ID: 37491748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
    Tu PHT; Anlay DZ; Dippenaar A; Conceição EC; Loos J; Van Rie A
    BMC Infect Dis; 2022 Nov; 22(1):876. PubMed ID: 36418994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.